Tilray Inc (NASDAQ:TLRY - Get Free Report)'s share price was down 4% during mid-day trading on Friday . The stock traded as low as $1.09 and last traded at $1.09. Approximately 8,179,247 shares were traded during trading, a decline of 80% from the average daily volume of 41,731,113 shares. The stock had previously closed at $1.13.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on TLRY shares. Roth Mkm decreased their price target on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a report on Friday, October 11th. Canaccord Genuity Group lifted their price target on shares of Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $2.70.
View Our Latest Stock Report on TLRY
Tilray Trading Up 6.5 %
The firm has a market cap of $998.61 million, a P/E ratio of -3.55 and a beta of 2.07. The business's 50-day moving average is $1.26 and its two-hundred day moving average is $1.54. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10.
Tilray (NASDAQ:TLRY - Get Free Report) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.07). Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. The company had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. Tilray's revenue for the quarter was up 8.7% on a year-over-year basis. As a group, analysts expect that Tilray Inc will post -0.2 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Tilray news, CFO Carl A. Merton purchased 26,000 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the acquisition, the chief financial officer now directly owns 26,000 shares of the company's stock, valued at approximately $35,360. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.87% of the company's stock.
Hedge Funds Weigh In On Tilray
Several institutional investors have recently modified their holdings of TLRY. Bank of Montreal Can boosted its position in Tilray by 0.3% during the third quarter. Bank of Montreal Can now owns 2,176,506 shares of the company's stock valued at $3,787,000 after purchasing an additional 7,406 shares during the last quarter. State Street Corp grew its holdings in shares of Tilray by 4.7% during the 3rd quarter. State Street Corp now owns 1,961,338 shares of the company's stock worth $3,452,000 after purchasing an additional 88,079 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Tilray by 1,314.1% in the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock valued at $3,202,000 after acquiring an additional 1,690,827 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Tilray by 6.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company's stock valued at $2,953,000 after acquiring an additional 107,530 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Tilray by 2.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,487,500 shares of the company's stock worth $2,617,000 after acquiring an additional 37,300 shares in the last quarter. 9.35% of the stock is currently owned by institutional investors and hedge funds.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Recommended Stories
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.